N-hydroxytetrahydrofuran-2-carbimidoyl chloride | 945989-04-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 英文名称: N-hydroxytetrahydrofuran-2-carbimidoyl chloride
• 英文别名: tetrahydrofuran-2-carbonyl chloride oxime；Tetrahydrofuran-2-carbonyl chloride oxime；N-hydroxyoxolane-2-carboximidoyl chloride
• CAS: 945989-04-8
• 化学式: C₅H₈ClNO₂
• 分子量: 149.577
• InChiKey: KIROQHGPPSNBRH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  41.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-hydroxytetrahydrofuran-2-carbimidoyl chloride 在 吡啶 、 sodium hydroxide 、 乙醇 、 水 、 三乙胺 作用下， 以 乙醚 、 乙腈 为溶剂， 反应 1.85h， 生成
  参考文献：
  名称：

  WO2007/89512

  摘要：

  公开号：
• 作为产物：
  描述：

  四氢呋喃-2-甲醛 在 N-氯代丁二酰亚胺 、 盐酸羟胺 、 sodium carbonate 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-hydroxytetrahydrofuran-2-carbimidoyl chloride
  参考文献：
  名称：

  Discovery and preclinical development of AR453588 as an anti-diabetic glucokinase activator

  摘要：

  Glucose flux through glucokinase (GK) controls insulin release from the pancreas in response to high levels of glucose. Flux through GK is also responsible for reducing hepatic glucose output. Since many individuals with type 2 diabetes appear to have an inadequacy or defect in one or both of these processes, identifying compounds that can activate GK could provide a therapeutic benefit. Herein we report the further structure activity studies of a novel series of glucokinase activators (GKA). These studies led to the identification of pyridine 7 2 as a potent GKA that lowered post-prandial glucose in normal C57BL/6J mice, and after 14d dosing in ob/ob mice.

  DOI：

  10.1016/j.bmc.2019.115232

文献信息

• 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS
  申请人：Aicher Thomas D.

  公开号：US20090156603A1

  公开（公告）日：2009-06-18

  Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes meilitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供了化学式I的化合物，这些化合物在治疗和/或预防由胰岛素活性不足引起的疾病中非常有用，例如糖尿病。还提供了治疗或预防由胰岛素活性不足或可以通过激活胰岛素来治疗的疾病和疾患的方法。
• GLUCOKINASE ACTIVATORS
  申请人：Aicher Thomas D.

  公开号：US20090247526A1

  公开（公告）日：2009-10-01

  Provided are compounds of formula I wherein R 2 , L, Z, Y, G and R 1 are as defined herein, that are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

  提供了化合物I的公式，其中R2、L、Z、Y、G和R1的定义如此处所述，这些化合物在治疗和/或预防由葡萄糖激酶活性不足介导的疾病或疾病中有用，或者可以通过激活葡萄糖激酶来治疗，包括但不限于糖尿病、糖耐量受损、IFG（空腹血糖受损）和IFG（空腹高血糖）以及其他疾病和疾病，如本文所讨论的。
• Glucokinase activators
  申请人：Array Biopharma, Inc.

  公开号：US08022222B2

  公开（公告）日：2011-09-20

  Provided are compounds of formula I wherein R2, L, Z, Y, G and R1 are as defined herein, that are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

  提供了公式I的化合物，其中R2，L，Z，Y，G和R1的定义如本文所述，它们可用于治疗和/或预防由于葡萄糖激酶活性不足引起或可以通过激活葡萄糖激酶治疗的疾病或疾病，包括但不限于糖尿病，糖耐量受损，IFG（空腹血糖受损）和IFG（空腹高血糖症），以及其他疾病和疾病，如本文所述。
• 2-aminopyridine analogs as glucokinase activators
  申请人：Array Biopharma, Inc.

  公开号：US08022223B2

  公开（公告）日：2011-09-20

  Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes meilitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供了I式化合物，可用于治疗和/或预防由葡萄糖激酶活性不足引起的疾病，例如糖尿病。还提供了治疗或预防葡萄糖激酶活性不足或可以通过激活葡萄糖激酶治疗的疾病和紊乱的方法。
• WO2007/89512
  申请人：——

  公开号：——

  公开（公告）日：——